Recent Security Class Actions

Tricida Inc. Common Stock (NASDAQ: TCDA)

Company Name:Tricida Inc. Common Stock
Stock Symbol:NASDAQ: TCDA
Class Period Start:09/04/2019
Class Period End (inclusive):10/28/2020
Filing Deadline:03/07/2021

According to the Complaint, Tricida, Inc. is a pharmaceutical company that focuses on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (“CKD”). Tricida has completed a Phase 3, double-blind, placebo-controlled trial of veverimer in patients with CKD and metabolic acidosis.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company’s business, operational, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and failed to disclose to investors that: (i) Tricida’s NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.